Navigation Links
ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Date:10/28/2009

espectively, compared to $33.0 million and $83.9 million, respectively, for the same periods in 2008. The decrease in adjusted net income for both periods is primarily due to lower Vancocin net sales, lower interest income and higher income tax expense due to lower qualified orphan drug spend for Maribavir. Offsetting these decreases is the net effect of the Cinryze launch and lower research and development expenses.

The change between our GAAP net loss for the nine months ended September 30, 2009 from GAAP net income in the same period of 2008 was the impact of our Goodwill impairment of $65 million and the $9.1 million gain on the repurchase of our convertible notes, in addition to the factors influencing our non-GAAP adjusted net income discussed above. The change in GAAP net income in the three months ended September 30, 2009 compared to 2008 was impacted by a $5.3 million increase in amortization related to the acquisition of Lev Pharmaceuticals, Inc. in addition to the factors influencing the non-GAAP adjusted net income.

Effective January 1, 2009, the Company was required under a new accounting standard to change the method of accounting for the Company's convertible notes. The Company revised its previously reported financial statements to apply this change in accounting to prior periods. Under this new accounting method, the Company's EPS and net (loss) income calculated in accordance with GAAP have been reduced as a result of recognizing incremental non-cash interest expense. In connection with adopting this new accounting standard, the Company recorded $1.8 million and $2.0 million of additional non-cash interest expense in the three months ended September 30, 2009 and 2008, respectively, and $5.5 million and $5.8 million for the nine months ended September 30, 2009 and 2008, respectively. For the three months ended September 30, 2008, the Company's previously reported net income calculated in accordance with GAAP changed slightly
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
2. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
3. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
4. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
5. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
6. ViroPharma Announces Discontinuation of HCV-796 Development
7. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
8. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. ViroPharma to Present at the Natixis Bleichroeder Conference
10. ViroPharma to Present at Three Upcoming Healthcare Conferences
11. Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... ANGELES , Aug. 29, 2014  Chuma ... both financing alternatives and turnkey support services for ... announce that FINRA processed and approved the Company,s ... 29, 2014, CannaMed Corporation will be known as ... change was accomplished through a merger with the ...
(Date:8/29/2014)... YORK , Aug. 29, 2014 Pomerantz ... TMS S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ... filed in United States District Court, Southern District of ... 14-cv-6069, is on behalf of a class consisting of ... February 1, 2013 and July 30, 2014, inclusive (the ...
(Date:8/29/2014)... 2014 Thoratec Corporation (NASDAQ: THOR ... therapies to save, support and restore failing hearts, said ... Stanley Global Healthcare Conference on Wednesday, September 10. ... Executive Officer, will provide an update on the company, ... Pacific Daylight Time).   A webcast of ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
... Inc., ("Dharma") Seattle, WA (a subsidiary of the Transcu ... Limited) announced that its improved active transdermal delivery technology, ... a mild electric current, has demonstrated safety and efficacy ... About the Trial: , , The trial conducted ...
... FRANCISCO, Calif., July 8 Rigel Pharmaceuticals, Inc. (Nasdaq: ... host a conference call on Thursday, July 9, 2009 at ... senior management team and the principal investigator of the trial ... trial of R788 in rheumatoid arthritis, the Company,s plans for ...
Cached Medicine Technology:Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial 2Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 "My wife ... of a car accident," said one of two inventors ... strain in her shoulder and neck area. She tried ... reduced pain and pressure, assisting in comfort and providing ... patent-pending PILLOW CRADLE to support the head, neck and ...
(Date:8/30/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Lab Oven Industry, 2009-2019 is a professional and ... Oven industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, production value, and market ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 Serving ... company in India, Profit By Outsourcing is now ... Development services. The company gives emphasize on putting forward ... complete product to clients. Their dedicated team of professionals ... ground-breaking results. They can handle even the critical issues ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... for transvaginal mesh lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed ... request to sever four cases selected for one ... Order issued on August 18, 2014, U.S. District ... of West Virginia disagrees with Boston Scientific’s contention ...
(Date:8/30/2014)... Transvenous lead extraction (TLE) is clinically successful in more ... European Lead Extraction ConTRolled (ELECTRa) registry presented for the ... Maria Grazia Bongiorni, chair of the registry,s executive committee. ... electronic devices (CIED) implant procedures has grown in recent ... has increased and leads are often the cause. TLE ...
Breaking Medicine News(10 mins):Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3
... knowledge about appetite regulation among people , , MONDAY, Dec. 15 ... be obese, based on the discovery of six additional genetic ... new study says. , The study by an ... , adds to previous research that linked two other genetic ...
... efficacy of The Pink Patch for weight control with ... in 4 weeks. The Pink Patch is a once-a-day ... loss goals. Dr. Hudson stated in her findings, ... dietary or activity changes, The Pink Patch, can potentially ...
... 15 The Endovascular Forum, Inc. (EVF), an ... Cardiovascular Angiography,and Interventions (SCAI), announced a collaboration to ... complex clinical skills,development in Cardiovascular medicine. The partnership ... developing a new generation of tools for,physicians to ...
... will provide an integrated approach to home-based care and support. , ... The launch of a new company aimed at promoting and supporting ... is introducing new programs and innovating existing services to help individuals ... , "Due to falling birthrates and increased life expectancy, ...
... American Chemical Society (ACS) News Service Weekly PressPac with ... & Engineering News .Please credit the individual journal or ... information. , , News Items in This Edition:, , ... countries outside U.S., Advance in the battle against "gray ...
... Achievements of Past Century Include Major Milestones in the Advancement ... , , ALEXANDRIA, Va., Dec. ... its Centennial Year: "Celebrating the Legacy, Forging the Future." ... story of one person who turned a personal struggle with ...
Cached Medicine News:Health News:Genetic Variants Tied to Obesity 2Health News:Double Blind Study Proves The Pink Patch Works for Weight Loss 2Health News:Double Blind Study Proves The Pink Patch Works for Weight Loss 3Health News:The Endovascular Forum, Inc. and the Society for Cardiovascular Angiography and Interventions Partner to Extend the Influence of Electronic Medical Care Innovation to Cardiovascular Medicine Through www.EndoVascular.Org, a Global, Multi-disciplinary Care 2Health News:The Endovascular Forum, Inc. and the Society for Cardiovascular Angiography and Interventions Partner to Extend the Influence of Electronic Medical Care Innovation to Cardiovascular Medicine Through www.EndoVascular.Org, a Global, Multi-disciplinary Care 3Health News:The Endovascular Forum, Inc. and the Society for Cardiovascular Angiography and Interventions Partner to Extend the Influence of Electronic Medical Care Innovation to Cardiovascular Medicine Through www.EndoVascular.Org, a Global, Multi-disciplinary Care 4Health News:Launch of New 'Independent Aging' Company Will Address the Needs of the Growing Senior Population 2Health News:Launch of New 'Independent Aging' Company Will Address the Needs of the Growing Senior Population 3Health News:ACS PressPac -- Dec. 10, 2008 2Health News:ACS PressPac -- Dec. 10, 2008 3Health News:ACS PressPac -- Dec. 10, 2008 4Health News:ACS PressPac -- Dec. 10, 2008 5Health News:ACS PressPac -- Dec. 10, 2008 6Health News:ACS PressPac -- Dec. 10, 2008 7Health News:Mental Health America Celebrates 100 Years of Mental Health Advocacy and Support 2Health News:Mental Health America Celebrates 100 Years of Mental Health Advocacy and Support 3
... is the ideal system for fast, accurate filling ... driven, pinch valve controlled dispensing mechanism, ensures that ... of the components that come into contact with ... and autoclave. The unique compact design saves valuable ...
... The QFill2 is the ideal system for ... plates. The pressure driven, pinch valve controlled dispensing ... system. Whilst all of the components that come ... to dismantle, clean, and autoclave. The unique compact ...
... Fill offers ... and reliable alternative ... dispensers. Fill guarantees ... dispensing without the ...
... Multidrop DW is a high-speed automated dispenser for ... 96-well plates. Designed for accuracy and precision, the ... It covers a volume range of 20-995 l. ... high-precision peristaltic pump to dispense directly from single ...
Medicine Products: